Gradient Investments LLC Acquires 12,436 Shares of Sanofi $SNY

Gradient Investments LLC increased its holdings in shares of Sanofi (NASDAQ:SNY) by 55.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,816 shares of the company’s stock after purchasing an additional 12,436 shares during the quarter. Gradient Investments LLC’s holdings in Sanofi were worth $1,687,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Financial Consulate Inc. bought a new position in Sanofi in the 3rd quarter worth approximately $26,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Sanofi during the third quarter valued at approximately $29,000. Palisade Asset Management LLC purchased a new position in shares of Sanofi in the third quarter worth $30,000. First Horizon Corp purchased a new position in shares of Sanofi in the third quarter worth $33,000. Finally, Salomon & Ludwin LLC boosted its position in shares of Sanofi by 1,046.3% during the third quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock worth $39,000 after acquiring an additional 701 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Trading Up 0.4%

SNY stock opened at $44.77 on Tuesday. The firm has a fifty day moving average price of $46.40 and a 200 day moving average price of $48.02. Sanofi has a fifty-two week low of $43.32 and a fifty-two week high of $56.93. The firm has a market cap of $109.19 billion, a PE ratio of 12.44, a price-to-earnings-growth ratio of 1.15 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09.

Analyst Ratings Changes

Several research firms recently weighed in on SNY. TD Cowen reaffirmed a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. HSBC reissued a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Finally, Wall Street Zen cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and a consensus target price of $61.50.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.